<DOC>
	<DOCNO>NCT01600170</DOCNO>
	<brief_summary>HIV associate neurological disorder ( HAND ) , major problem even ART treat people . HAND result chronic inflammation largely attributed expansion activation monocyte . These activated monocyte , also carry virus brain , invade CNS release cytokine / chemokines result recruitment monocyte , well release viral protein injure neuron cause activation brain cell . Persistent monocyte/macrophage activation thus potential critical target adjunctive therapy treat prevent HAND . The investigator therefore propose study effect statin drug ( Atorvastatin ) , anti-inflammatory function , monocyte activation status vitro ART treat HIV+ individual . The investigator objective base hypothesis Atorvastatin treatment reduce inflammatory activate phenotype function monocyte link HIV associate neuropathogenesis occur HIV infect subject despite ART . In study investigator propose 1. determine Atorvastatin modulate monocyte activation , intracellular signal pathways function implicate pathogenesis HAND vitro 2. define effect Atorvastatin monocyte activation HIV infect / ART treat subject double blind , placebo control crossover study 3. define gene expression patter monocyte activation follow statin treatment 4. ass Atorvastatin effect CNS immune activation marker neurocognitive function ART treat subject .</brief_summary>
	<brief_title>Downmodulating Monocyte Activation HIV-1 Associated Neurocognitive Disorders ( HAND )</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Neurocognitive Disorders</mesh_term>
	<mesh_term>AIDS Dementia Complex</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>1 . Chronic HIV1 infect individual HAART ( change treatment within 4 week study entry ) willing continue therapy duration study . 2 . HIV viral load le 200 copies/ml 6 month time screen . 3 . Nadir CD4 count le 350 current CD4 count great 100 cells/ul . 4 . HsCRP level 2mg/L . 5 . Willingness use method contraception study period . 6 . Willingness comply study evaluation LP substudy . 7 . Karnofsky performance score 80 high . 8 . If female , willing undergo pregnancy test monthly basis breastfeeding . 9 . Hemoglobin great equal 9.0 g/dL female 10.0 g/dL male subject . 10. men woman 18 year old . 1 . Concomitant use fibric acid derivative lipid lower agent include patient statins Ezetimibe . 2 . Use antiinflammatory drug ( OTC prescription ) daily basis . 3 . Pregnancy breastfeed 4 . Active drug use alcohol abuse/dependence opinion researcher interfere patient ' ability participate study . 5 . Allergy hypersensitivity Atorvastatin component . 6 . History myositis rhabdomyolysis use statin . 7 . Patients concurrent immunomodulatory agent , include systemic corticosteroid ( nasal inhale ) ineligible 3 month completion therapy agent . 8 . History inflammatory muscle disease poly dermatomyositis . 9 . Serious intercurrent illness require systemic treatment and/or hospitalization within 30 day entry . 10 . Evidence active opportunistic infection require treatment neoplasm require chemotherapy study period . 11 . CPK great 3 time ULN . 12 . Known active liver disease AST/ALT great 3 time ULN . 13 . Renal insufficiency , indicate serum creatinine great 2mg/dL . 14 . Absolute neutrophil count less 1000/ul ; hemoglobin le 10g/dL male less 9g/dL female ; platelet count less 100,000/mm3 . 15 . Documented HCV infection . 16 . NYHA class III IV congestive heart failure . 17 . Active IV drug use within 1 year prior entry . 18 . For LP substudy , allergy Lidocaine . 19 . Coronary artery disease equivalent include Diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>monocyte</keyword>
	<keyword>CD16+</keyword>
	<keyword>statin</keyword>
	<keyword>mcp1</keyword>
	<keyword>inflammation</keyword>
</DOC>